Merck coformulation fails to meet key goal in lung cancer trial (NYSE:MRK)
Merck (NYSE:MRK) stated on Thursday that its investigational coformulation for metastatic non-small cell lung most cancers (NSCLC) didn't present an ...
Tag: coformulation
